2024 ESMO｜新研究，最看点！8大令人振奋的新型靶向药物前瞻

摘要号及标题：

603O - PRT3789（一种同类首创的静脉注射 SMARCA2降解剂）在 SMARCA4 基因突变的晚期实体瘤患者中的首次临床试验结果

603O - First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation

专场：Proffered paper session 1: Developmental therapeutics

讲者：Robin Guo (New York, United States of America)

讲座时间：2024.9.13 16:00-16:10

摘要号及标题：

608O - ASP3082（一种首创的选择性 KRAS G12D 蛋白降解剂）在晚期胰腺癌成人患者中的初步安全性和临床活性在晚期胰腺癌（PC）、结直肠癌（CRC）和非小细胞肺癌（NSCLC）成人患者中的初步安全性和临床活性

608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

专场：Proffered paper session 2: Developmental therapeutics

讲者：Wungki Park (New York, United States of America)

讲座时间：2024.9.15 14:45-14:55

摘要号及标题：

LBA27 - STX-478（一种PI3Ka突变选择性抑制剂）在晚期实体瘤患者中的首次人体试验结果

LBA27 - First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

专场：Proffered paper session 2: Developmental therapeutics

讲者：Alberto J. Montero (Cleveland, United States of America)

讲座时间：2024.9.15 14:55-15:05

摘要号及标题：

LBA78 - MOTION研究：Vimseltinib（一种CSF-1R激酶抑制剂）治疗腱鞘巨细胞瘤（TGCT）患者的最新疗效和安全性的III期试验的1年随访结果

LBA78 - Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 1-year follow-up from the MOTION phase 3 trial

专场：Proffered paper session: Sarcoma

讲者：Hans Gelderblom (Leiden, Netherlands)

讲座时间：2024.9.16 15:25-15:35

摘要号及标题：

LBA82 - Ponsegromab（一种生长分化因子15 单克隆抗体抑制剂）对癌症恶病质患者的疗效和安全性：一项随机、安慰剂对照的 2 期研究

LBA82 - Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase 2 study

专场：Proffered paper session: Supportive and palliative care

讲者：Jeffrey Crawford (Durham, United States of America, NC)

讲座时间：2024.9.14 15:22-15:32

摘要号及标题：

996MO - Dazostinag（TAK-676，一种新型合成STING激动剂）单独或联合帕博利珠单抗（pembro）治疗晚期/转移性实体瘤患者：1期剂量递增研究结果

996MO - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation

专场：Mini oral session: Investigational immunotherapy

讲者：Jason J. Luke (Pittsburgh, United States of America)

讲座时间：2024.9.16 10:45-10:50

摘要号及标题：

619MO - Camonsertib（一种选择性ATR口服小分子抑制剂）单药治疗携带 ATM 功能缺失（LoF）的晚期癌症患者

619MO - Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)

专场：Mini oral session: Developmental therapeutics

讲者：Benedito A. Carneiro (Providence, United States of America)

讲座时间：2024.9.14 15:45-15:50

摘要号及标题：

516MO - Zanidatamab (Zani，HER2双特异性抗体) + 化疗 (CT) 一线 (1L) 治疗人表皮生长因子受体 2 阳性 (HER2+) 晚期/转移性结直肠癌 (mCRC)

516MO - Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic colorectal cancer (mCRC)

专场：Mini oral session: GI tumours, lower

讲者：Sun Young Rha (Seoul, Korea, Republic of)

讲座时间：2024.9.14 14:50-14:55